184 related articles for article (PubMed ID: 29945960)
1. Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
Hong SY; Kao YR; Lee TC; Wu CW
Cancer Res; 2018 Sep; 78(17):4984-4996. PubMed ID: 29945960
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.
Hong SY; Lu YC; Hsiao SH; Kao YR; Lee MH; Lin YP; Wang CY; Wu CW
Oncogene; 2022 Mar; 41(13):1907-1917. PubMed ID: 35149839
[TBL] [Abstract][Full Text] [Related]
3. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
5. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
6. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
[TBL] [Abstract][Full Text] [Related]
8. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
9. Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling.
Zhong D; Ru Y; Wang Q; Zhang J; Zhang J; Wei J; Wu J; Yao L; Li X; Li X
Cancer Lett; 2015 Apr; 359(1):57-64. PubMed ID: 25573345
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
Zhang S; Sun Y
EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
[No Abstract] [Full Text] [Related]
11. LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
Zhu T; An S; Choy MT; Zhou J; Wu S; Liu S; Liu B; Yao Z; Zhu X; Wu J; He Z
J Cell Mol Med; 2019 Mar; 23(3):1852-1864. PubMed ID: 30515972
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
[TBL] [Abstract][Full Text] [Related]
13. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
14. Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH.
Courbard JR; Fiore F; Adélaïde J; Borg JP; Birnbaum D; Ollendorff V
J Biol Chem; 2002 Nov; 277(47):45267-75. PubMed ID: 12226085
[TBL] [Abstract][Full Text] [Related]
15. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Shao G; Wang R; Sun A; Wei J; Peng K; Dai Q; Yang W; Lin Q
Mol Cancer; 2018 Feb; 17(1):24. PubMed ID: 29455656
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
17. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
18. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.
Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J
Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632
[No Abstract] [Full Text] [Related]
20. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
